津药药业股份有限公司 2025 年第三次临时股东大会 津药药业股份有限公司 2025 年第三次临时股东大会 会议资料 2025 年 8 月 津药药业股份有限公司 2025 年第三次临时股东大会 津药药业 2025 年第三次临时股东大会会议议案之一 关于变更经营范围、取消监事会、修订《津药药业股 份有限公司章程》并办理工商变更的议案 1 / 99 津药药业股份有限公司 2025 年第三次临时股东大会 | 目录 | | --- | | 1.关于变更经营范围、取消监事会、修订《津药药业股份有限公司章 | | --- | | 程》并办理工商变更的议案 3 | | 2.关于修订《股东会议事规则》的议案 63 | | 3.关于修订《董事会议事规则》的议案 80 | | 4.关于修订《独立董事工作制度》的议案 91 | 2 / 99 (已经 2025 年 7 月 25 日第九届董事会第 19 次会议审议通过) 为提高公司规范运作水平，进一步完善公司治理制度，提升公司 运营效率，根据《公司法》《上市公司章程指引》等相关规定，公司 将不再设置监事会和监事，由董事会审计与风险控制委员会履行《公 司法》规定的监事会职权，同时，结合 ...

近日，津药药业股份有限公司（以下简称"公司"）收到天津市药品监督管理局签发的《药品GMP符合 性检查告知书》（编号：2025011），现将相关信息公告如下： 一、 基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 （二）涉及主要产品的市场情况 ■ 企业名称：津药药业股份有限公司 检查地址：天津开发区西区新业九街19号 检查范围：1.原料药(泼尼松)，生产车间:107车间，生产线:泼尼松生产B线；2.原料药(甲泼尼龙)，生产 车间:113车间，生产线:甲泼尼龙生产B线；3.原料药(氢化可的松琥珀酸钠)，生产车间:106车间，生产 线:氢化可的松琥珀酸钠生产线;4.原料药(富马酸福莫特罗)，生产车间:108车间，生产线:富马酸福莫特 罗生产线。 检查时间：2025年05月13日-2025年05月16日 检查依据：《药品生产质量管理规范》(2010年修订) 检查结论：符合要求 二、其他相关情况 （一）本次检查所涉及生产线及主要产品情况 ■ 注: 1.以上部分数据来源为国家药品监督管理局官方网站； 2.上述统计结果可能不 ...

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

（文章来源：证券日报） 证券日报网讯 7月31日晚间，津药药业发布公告称，近日，公司收到天津市药品监督管理局签发的《药 品GMP符合性检查告知书》（编号：2025011）。 ...

证券代码：600488 证券简称：津药药业 编号：2025-049 津药药业股份有限公司 关于收到药品 GMP 符合性检查结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）收到天津市药品监督管理局签 发的《药品 GMP 符合性检查告知书》（编号：2025011），现将相关信息公告如下： 一、 基本情况 企业名称：津药药业股份有限公司 检查地址：天津开发区西区新业九街 19 号 检查范围：1.原料药(泼尼松)，生产车间:107 车间，生产线:泼尼松生产 B 线；2. 原料药(甲泼尼龙)，生产车间:113 车间，生产线:甲泼尼龙生产 B 线；3.原料药(氢化可 的松琥珀酸钠)，生产车间:106 车间，生产线:氢化可的松琥珀酸钠生产线;4.原料药(富 马酸福莫特罗)，生产车间:108 车间，生产线:富马酸福莫特罗生产线。 检查时间：2025 年 05 月 13 日-2025 年 05 月 16 日 检查依据：《药品生产质量管理规范》(2010 年修订) 检查结论：符合要求 ...

Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) has received a GMP compliance inspection notice from the Tianjin Drug Administration, indicating that its production facilities for certain raw materials meet regulatory requirements, which is expected to support stable production capacity and leverage the integrated advantages of raw materials and formulations [2] Group 1 - The company received a GMP compliance inspection notice for its production facilities related to raw materials including prednisone, methylprednisolone, hydrocortisone sodium succinate, and formoterol fumarate [2] - The inspection concluded that the production facilities meet the required standards, which is beneficial for maintaining stable production capacity [2] - The integrated advantages of raw materials and formulations will help the company meet market demand [2] Group 2 - Future sales of the products may be influenced by changes in the market environment, indicating potential uncertainties [2]

证券代码：600488 证券简称：津药药业 编号：2025-048 三、同类药品市场情况 根据米内网全国放大版的医院数据（含城市公立医院、县级公立医院、城市药店、网上药店、城市社区 医院、乡镇卫生院）显示，2023年、2024年腹膜透析液（乳酸盐-G1.5%）国内销售额为15.48亿元、 16.89亿元。2023年、2024年腹膜透析液（乳酸盐-G2.5%）国内销售额为7.43亿元、8.40亿元。 四、影响及风险提示 根据国家相关政策规定，对于通过一致性评价的药品品种，在医保支付方面予以适当支持，医疗机构应 优先采购并在临床中优先选用。津药和平腹膜透析液（乳酸盐）通过一致性评价，有利于提升该药品的 市场竞争力。由于药品研发、生产和销售容易受到国家政策、市场环境等因素影响，具有较大不确定 性，敬请广大投资者谨慎决策，注意防范投资风险。 津药药业股份有限公司关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天津）制药有限公司 ...

Core Viewpoint - Tianyao Pharmaceutical's subsidiary Tianyao Heping has received approval for two types of peritoneal dialysis solutions, which will enhance the company's market competitiveness in this product line [1][2]. Group 1: Product Approval and Market Impact - Tianyao Heping's peritoneal dialysis solutions (lactate-G1.5% and lactate-G2.5%) have passed the consistency evaluation for generic drugs, allowing them to be marketed [1]. - The domestic sales forecast for lactate-G1.5% is projected to be 1.548 billion yuan in 2023 and 1.689 billion yuan in 2024, while lactate-G2.5% is expected to generate sales of 743 million yuan in 2023 and 840 million yuan in 2024 [1]. - The approval will lead to appropriate support in medical insurance payments and priority procurement by medical institutions [1]. Group 2: Company Strategy and Development - The company is committed to an integrated development strategy of raw materials and formulations, focusing on steroid hormones and amino acid raw materials [2]. - Tianyao Pharmaceutical has made significant progress in new product research and development, consistency evaluation, and drug registration, with 32 products passing the consistency evaluation and 18 obtaining drug registration certificates [2]. - Several key formulation products have achieved annual sales exceeding 100 million yuan [2].

证券日报网讯 7月29日晚间，津药药业发布公告称，近日，公司子公司津药和平（天津）制药有限公司 收到国家药品监督管理局核准签发的腹膜透析液（乳酸盐）（以下简称"本品"）的《药品补充申请批准 通知书》，批准本品通过仿制药质量和疗效一致性评价（简称"一致性评价"）。 （编辑 楚丽君） ...

Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]